Kamal D. Puri

Kamal D. Puri has more than 20 years of research and development experience in immunology, oncology, and neurobiology. Kamal Puri joined OncoResponse from Celgene, where he discovered new molecular entities for the immunology pipeline and identified and supported new indications for portfolio molecules. Prior to Celgene, Kamal Puri was Associate Director of Research at Gilead and contributed to the approval of Zydelig™ a first-in-class PI3K delta inhibitor for the treatment of hematological malignancies, and he led efforts for a best-in-class PI3K delta inhibitor and advanced it into clinical development, and directed research efforts on multiple discovery projects in inflammation. Prior to Gilead, Kamal Puri was Head of Biology at Calistoga Pharma, where he was responsible for a wide range of activities with success in advancing three drug candidates into clinical development for multiple indications. Kamal Puri undertook his immunology training with Timothy A. Springer, Ph.D. at the Harvard Medical School.

Kamal D. Puri is the Chief Scientific Officer at OncoResponse, based in United States, North America. With a background in Biotechnology, Kamal D. Puri has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.